DELCATH SYSTEMS, INC.
Develops targeted chemotherapy delivery systems for treating primary and metastatic liver cancers.
DCTH | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 566 QUEENSBURY AVENUE, 12804 QUEENSBURY
- Website:
- https://delcath.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of medical and dental instruments and supplies
Description
Delcath Systems, Inc. is a commercial-stage, interventional oncology company focused on treating primary and metastatic liver cancers. The company develops and commercializes specialty pharmaceutical and medical device products based on its proprietary percutaneous hepatic perfusion (PHP) technology. This minimally-invasive procedure is designed to deliver high-dose chemotherapy directly to the liver while controlling systemic side effects. Its flagship products are the HEPZATO KIT™, recently FDA-approved in the U.S. for treating metastatic uveal melanoma, and the CHEMOSAT® Hepatic Delivery System, a medical device available in Europe. Delcath aims to provide targeted, minimally-invasive treatment options for patients with liver-dominant cancers.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all DELCATH SYSTEMS, INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for DELCATH SYSTEMS, INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for DELCATH SYSTEMS, INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
